Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Derosa

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Cell Metabolism|March 2, 2022
Modulation of cancer immunotherapy by dietary fibers and over-the-counter probioticsLaurence Zitvogel, Lisa Derosa, Guido Kroemer
Bulletin Du Cancer|January 1, 2019
Ronan Flippot, Lisa Derosa, Laurence Albiges
Blood Cancer Discovery|April 20, 2023
Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic MalignanciesLaurence Zitvogel, Lisa Derosa, Guido Kroemer
Oncology Reviews|December 21, 2016
Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaLisa Derosa, Hassane Izzedine, Laurence Albiges, et al.
Oncoimmunology|June 7, 2018
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1Lisa Derosa, Bertrand Routy, Guido Kroemer, et al.
ESMO Open|May 12, 2020
New pathways in immune stimulation: targeting OX40Carolina Alves Costa Silva, Francesco Facchinetti, Bertrand Routy, et al.
Gut Microbes|October 20, 2018
The intimate relationship between gut microbiota and cancer immunotherapyArielle Elkrief, Lisa Derosa, Laurence Zitvogel, et al.
Nature Reviews. Urology|July 11, 2023
From mucosal infection to successful cancer immunotherapyAnne-Gaëlle Goubet, Mathieu Rouanne, Lisa Derosa, et al.
Expert Opinion on Drug Safety|May 5, 2016
Safety of available treatment options for renal cell carcinomaLisa Derosa, Laurence Albiges, Christophe Massard, et al.
Angiogenesis|February 11, 2019
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validationLisa Derosa, Mohamed Amine Bayar, Laurence Albiges, et al.
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Cell Metabolism|March 2, 2022
Modulation of cancer immunotherapy by dietary fibers and over-the-counter probioticsLaurence Zitvogel, Lisa Derosa, Guido Kroemer
Bulletin Du Cancer|January 1, 2019
Ronan Flippot, Lisa Derosa, Laurence Albiges
Blood Cancer Discovery|April 20, 2023
Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic MalignanciesLaurence Zitvogel, Lisa Derosa, Guido Kroemer
Oncology Reviews|December 21, 2016
Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaLisa Derosa, Hassane Izzedine, Laurence Albiges, et al.
Oncoimmunology|June 7, 2018
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1Lisa Derosa, Bertrand Routy, Guido Kroemer, et al.
ESMO Open|May 12, 2020
New pathways in immune stimulation: targeting OX40Carolina Alves Costa Silva, Francesco Facchinetti, Bertrand Routy, et al.
Gut Microbes|October 20, 2018
The intimate relationship between gut microbiota and cancer immunotherapyArielle Elkrief, Lisa Derosa, Laurence Zitvogel, et al.
Nature Reviews. Urology|July 11, 2023
From mucosal infection to successful cancer immunotherapyAnne-Gaëlle Goubet, Mathieu Rouanne, Lisa Derosa, et al.
Expert Opinion on Drug Safety|May 5, 2016
Safety of available treatment options for renal cell carcinomaLisa Derosa, Laurence Albiges, Christophe Massard, et al.
Angiogenesis|February 11, 2019
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validationLisa Derosa, Mohamed Amine Bayar, Laurence Albiges, et al.
Pageof 11